2.33
price up icon1.30%   0.03
pre-market  Vorhandelsmarkt:  2.30   -0.03   -1.29%
loading
Schlusskurs vom Vortag:
$2.30
Offen:
$2.314
24-Stunden-Volumen:
20,814
Relative Volume:
0.09
Marktkapitalisierung:
$89.87M
Einnahmen:
$2.70M
Nettoeinkommen (Verlust:
$5.53M
KGV:
21.18
EPS:
0.11
Netto-Cashflow:
$-10.55M
1W Leistung:
+8.37%
1M Leistung:
+0.00%
6M Leistung:
-1.48%
1J Leistung:
+1.30%
1-Tages-Spanne:
Value
$2.2801
$2.34
1-Wochen-Bereich:
Value
$2.1301
$2.34
52-Wochen-Spanne:
Value
$1.82
$3.09

Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile

Name
Firmenname
Oramed Pharmaceuticals Inc
Name
Telefon
646-844-1164
Name
Adresse
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Name
Mitarbeiter
0
Name
Twitter
@OramedPharma
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
ORMP's Discussions on Twitter

Vergleichen Sie ORMP mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ORMP
Oramed Pharmaceuticals Inc
2.33 89.87M 2.70M 5.53M -10.55M 0.11
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-01-12 Herabstufung Canaccord Genuity Buy → Hold
2022-02-18 Eingeleitet Cantor Fitzgerald Overweight
2021-04-20 Eingeleitet Canaccord Genuity Buy
2021-02-09 Eingeleitet National Securities Buy
2020-12-03 Eingeleitet Alliance Global Partners Buy
2020-03-11 Eingeleitet Aegis Capital Buy
2019-09-11 Eingeleitet Ladenburg Thalmann Buy
2017-12-11 Fortgesetzt B. Riley FBR, Inc. Buy
2016-05-26 Bestätigt FBR Capital Outperform
2015-12-01 Bestätigt H.C. Wainwright Buy
2015-11-19 Eingeleitet FBR Capital Outperform
2015-04-13 Fortgesetzt MLV & Co Buy
2014-01-30 Bestätigt Aegis Capital Buy
2014-01-08 Bestätigt Aegis Capital Buy
2014-01-08 Eingeleitet MLV & Co Buy
2013-12-03 Eingeleitet Aegis Capital Buy
Alle ansehen

Oramed Pharmaceuticals Inc Aktie (ORMP) Neueste Nachrichten

pulisher
Apr 24, 2025

ORMPOramed Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan

Apr 24, 2025
pulisher
Apr 10, 2025

Oramed stock hits 52-week low at $1.95 amid market challenges - Investing.com Australia

Apr 10, 2025
pulisher
Apr 09, 2025

Oramed stock hits 52-week low at $1.95 amid market challenges By Investing.com - Investing.com South Africa

Apr 09, 2025
pulisher
Mar 24, 2025

Oral Biologics Market Is Booming Worldwide 2025-2032 | Biocon - openPR.com

Mar 24, 2025
pulisher
Mar 21, 2025

Oramed Pharmaceuticals Inc expected to post a loss of 2 cents a shareEarnings Preview - TradingView

Mar 21, 2025
pulisher
Mar 13, 2025

Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential - Simply Wall St

Mar 13, 2025
pulisher
Mar 12, 2025

Oramed Pharmaceuticals Stock Plummets After Insulin Test Results - The Wall Street Journal

Mar 12, 2025
pulisher
Mar 11, 2025

Tianhui Biotech and Oramed Pharmaceuticals’ Investment in OraTech Pharmaceuticals - Global Legal Chronicle

Mar 11, 2025
pulisher
Mar 08, 2025

AllPennyStocks.com Releases a Special Report on Oramed Pharmaceuticals Inc. - ACCESS Newswire

Mar 08, 2025
pulisher
Mar 04, 2025

Oramed advances oral insulin, plans Phase 3 trial and dividend - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

Oramed advances oral insulin, plans Phase 3 trial and dividend By Investing.com - Investing.com South Africa

Mar 04, 2025
pulisher
Mar 04, 2025

Oramed Pharmaceuticals Issues Letter to Shareholders - PR Newswire

Mar 04, 2025
pulisher
Mar 03, 2025

ORMP stock touches 52-week low at $2 amid market challenges By Investing.com - Investing.com South Africa

Mar 03, 2025
pulisher
Mar 03, 2025

ORMP stock touches 52-week low at $2 amid market challenges - Investing.com

Mar 03, 2025
pulisher
Mar 01, 2025

Short Interest in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Expands By 149.0% - Armenian Reporter

Mar 01, 2025
pulisher
Feb 28, 2025

OraMed Enters Global Licensing Deal for Lidocaine Product By Investing.com - Investing.com Australia

Feb 28, 2025
pulisher
Feb 27, 2025

Oramed Pharmaceuticals (ORMP) to Release Quarterly Earnings on Wednesday - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

OraMed Enters Global Licensing Deal for Lidocaine Product - Investing.com India

Feb 27, 2025
pulisher
Feb 27, 2025

Rep. Brad Knott Sells Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Shares - MarketBeat

Feb 27, 2025
pulisher
Feb 26, 2025

Congressional Trading Report: Rep. Brad Knott Sold Over $15K In Oramed Pharmaceuticals Stock - Benzinga

Feb 26, 2025
pulisher
Feb 26, 2025

Congress Trade: Representative Brad Knott Just Disclosed New Stock Trades - Quiver Quantitative

Feb 26, 2025
pulisher
Feb 22, 2025

Oramed Pharmaceuticals (NASDAQ:ORMP) Downgraded to Sell Rating by StockNews.com - MarketBeat

Feb 22, 2025
pulisher
Feb 17, 2025

227,239 Shares in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Acquired by Peapod Lane Capital LLC - MarketBeat

Feb 17, 2025
pulisher
Feb 15, 2025

Oramed announces spinoff of protein drug technology - MSN

Feb 15, 2025
pulisher
Feb 12, 2025

OraTech to pioneer oral insulin with $75 million investment - MSN

Feb 12, 2025
pulisher
Feb 12, 2025

Oramed Pharmaceuticals : Ancillary Agreement Completion Protocol and Supplemental Agreement - Marketscreener.com

Feb 12, 2025
pulisher
Feb 11, 2025

Oramed Pharmaceuticals And 2 Other US Penny Stocks To Watch - Simply Wall St

Feb 11, 2025
pulisher
Feb 11, 2025

Oramed Pharm Amends Joint Venture for OraTech Launch - TipRanks

Feb 11, 2025
pulisher
Feb 11, 2025

Oramed (ORMP) Stock Skyrockets Amid JV Development Plans - Stocks Telegraph

Feb 11, 2025
pulisher
Feb 11, 2025

OraTech to pioneer oral insulin with $75 million investment By Investing.com - Investing.com South Africa

Feb 11, 2025
pulisher
Feb 11, 2025

Oramed Pharmaceuticals Forms Joint Venture to Commercialize Oral Insulin; Shares Rise - Marketscreener.com

Feb 11, 2025
pulisher
Feb 11, 2025

Oramed Pharmaceuticals to Spin Off Its Protein Oral Delivery Technology - Contract Pharma

Feb 11, 2025
pulisher
Feb 11, 2025

Oramed stock soars on spinoff plans (ORMP:NASDAQ) - Seeking Alpha

Feb 11, 2025
pulisher
Feb 11, 2025

Oramed Announces Joint Venture To Develop And Commercialize Oral Insulin -February 11, 2025 at 09:17 am EST - Marketscreener.com

Feb 11, 2025
pulisher
Feb 11, 2025

Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin - PR Newswire

Feb 11, 2025
pulisher
Feb 11, 2025

Charting the Course: Viking Therapeutics Inc’s VKTX Stock Prospects - The InvestChronicle

Feb 11, 2025
pulisher
Feb 11, 2025

Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Lowered by StockNews.com - MarketBeat

Feb 11, 2025
pulisher
Feb 10, 2025

Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Crosses Below 200 Day Moving AverageTime to Sell? - MarketBeat

Feb 10, 2025
pulisher
Feb 04, 2025

Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Passes Below 200 Day Moving AverageHere's What Happened - MarketBeat

Feb 04, 2025
pulisher
Jan 31, 2025

Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Cross Below Two Hundred Day Moving Average – Here’s Why - Defense World

Jan 31, 2025
pulisher
Jan 24, 2025

Oramed Pharmaceuticals Extends Maturity Date of Senior Secured Promissory Note in Recent Amendment - Defense World

Jan 24, 2025
pulisher
Jan 22, 2025

Oramed Pharmaceuticals extends loan maturity, acquires Scilex shares - Investing.com

Jan 22, 2025

Finanzdaten der Oramed Pharmaceuticals Inc-Aktie (ORMP)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Kapitalisierung:     |  Volumen (24h):